Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: Focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody

Nuclear Medicine and Biology

Volumn 38, Issue 8, 2011, Pages 1093-1102

  Malmberg, Jennie ^a   Sandström, Mattias ^b   Wester, Kenneth ^a   Tolmachev, Vladimir ^a   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Affibody molecule; Biodistribution; HER2; Prostate cancer; Radiolabeling; Trastuzumab

Indexed keywords

ABY 025; ABY 025 I 125; ABY 025 IN 111; N SUCCINIMIDYL 4 IODOBENZOIC ACID I 125; PENTETIC ACID; RADIOISOTOPE; TETRAXETAN; TRASTUZUMAB; TRASTUZUMAB I 125; TRASTUZUMAB IN 111; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; RADIOACTIVITY; RADIOIODINATION; SCINTISCANNING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; STAPHYLOCOCCAL PROTEIN A; TISSUE DISTRIBUTION;

EID: 82655172565     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.04.005     Document Type: Article

References (51)

1. American Cancer Society Cancer facts & figures 2010 2010, American Cancer Society, Atlanta (Ga).
2. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12(6):1665-1671.
3. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(15):1502-1512. for the TAX 327 Investigators.
4. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351(15):1513-1520.
5. Stavridi F., Karapanagiotou E.M., Syrigos K.N. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010, 36(2):122-130.
6. Signoretti S., Montironi R., Manola J., Altimari A., Tam C., Bubley G., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000, 92(23):1918-1925.
7. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
8. Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5(3):280-285.
9. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994, 54(20):5474-5478.
10. Gioeli D., Ficarro S.B., Kwiek J.J., Aaronson D., Hancock M., Catling A.D., et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002, 277(32):29304-29314.
11. Scher H.I., Sawyers C.L. Biology of castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23(32):8253-8261.
12. So A., Gleave M., Hurtado-Col A., Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005, 23(1):1-9.
13. Bacus S.S., Altomare D.A., Lyass L., Chin D.M., Farrell M.P., Gurova K., et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002, 21(22):3532-3540.
14. Carlsson J., Nordgren H., Sjöström J., Wester K., Villman K., Bengtsson N.O., et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004, 90(12):2344-2348.
15. Agus D.B., Scher H.I., Higgins B., Fox W.D., Heller G., Fazzari M., et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999, 59(19):4761-4764.
16. Ziada A., Barqawi A., Glode L.M., Varella-Garcia M., Crighton F., Majeski S., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004, 60(4):332-337.
17. Lara P.N., Chee K.G., Longmate J., Ruel C., Meyers F.J., Gray C.R., et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004, 100(10):2125-2131.
18. Sridhar S.S., Hotte S.J., Chin J.L., Hudes G.R., Gregg R., Trachtenberg J., et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 2010, 33(6):609-613.
19. Smith T.A. Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol 2010, 83(992):638-644.
20. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008, 14(28):2999-3019.
21. Dijkers E.C., de Vries E.G., Kosterink J.G., Brouwers A.H., Lub-de Hooge M.N. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des 2008, 14(31):3348-3362.
22. Lub-de Hooge M.N., Kosterink J.G., Perik P.J., Nijnuis H., Tran L., Bart J., et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004, 143(1):99-106.
23. Garmestani K., Milenic D.E., Plascjak P.S., Brechbiel M.W. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 2002, 29(5):599-606.
24. Orlova A., Wållberg H., Stone-Elander S., Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50(3):417-425.
25. Oude Munnink T.H., Korte M.A., Nagengast W.B., Timmer-Bosscha H., Schröder C.P., Jong J.R., et al. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010, 46(3):678-684.
26. Milenic D.E., Wong K.J., Baidoo K.E., Nayak T.K., Regino C.A., Garmestani K., Brechbiel M.W. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010, 2(5):550-564.
27. Behr T.M., Béhé M., Wörmann B. Trastuzumab and breast cancer. N Engl J Med 2001, 345(13):995-996.
28. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24(15):2276-2282.
29. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87(5):586-592.
30. Nygren P.A. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008, 275(11):2668-2676.
31. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010, 584(12):2670-2680.
32. Orlova A., Magnusson M., Eriksson T., Nilsson M., Larsson B., Höiden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006, 66(8):4339-4348.
33. Ahlgren S., Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010, 11(6):581-589.
34. Baum R.P., Prasad V., Müller D., Schuchardt C., Orlova A., Wennborg A., et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 2010, 51(6):892-897.
35. Feldwisch J., Tolmachev V., Lendel C., Herne N., Sjöberg A., Larsson B., et al. Design of an optimized scaffold for Affibody molecules. J Mol Biol 2010, 398(2):232-247.
36. Ahlgren S., Orlova A., Wållberg H., Hansson M., Sandström M., Lewsley R., et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 2010, 51(7):1131-1138.
37. Malmberg J., Tolmachev V., Orlova A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer. Cellular processing of 111In-labeled CHX-A-DTPA-trastuzumab and anti-HER2 ABY-025 Affibody molecule by prostate cancer cell lines. Exp Ther Med 2011, 2:523-528.
38. Wållberg H., Orlova A. Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008, 23(4):435-442.
39. Almqvist Y., Steffen A.C., Tolmachev V., Divgi C.R., Sundin A. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol 2006, 33(8):991-998.
40. Paavilainen L., Wernérus H., Nilsson P., Uhlén M., Hober S., Wester K., Pontén F. Appl Immunohistochem Mol Morphol 2008, 16(5):493-502.
41. Tolmachev V., Wållberg H., Sandström M., Hansson M., Wennborg A., Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011, 38(3):531-539.
42. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Slamon D.J., Fendly B.M., Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990, 45(3):457-461.
43. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5(7):953-962.
44. Badger C.C., Wilbur D.S., Hadley S.W., Fritzberg A.R., Bernstein I.D. Biodistribution of p-iodobenzoyl (PIP) labeled antibodies in a murine lymphoma model. Int J Rad Appl Instrum B 1990, 17(4):381-387.
45. Hadley S.W., Wilbur D.S., Gray M.A., Atcher R.W. Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate. Bioconjug Chem 1991, 2(3):171-179.
46. Orlova A., Höglund J., Lubberink M., Lebeda O., Gedda L., Lundqvist H., et al. Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implication for in vivo dosimetry. Cancer Biother Radiopharm 2002, 17(4):385-396.
47. De León-Rodríguez L.M., Kovacs Z. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 2008, 19(2):391-402.
48. Parry R., Schneider D., Hudson D., Parkes D., Xuan J.A., Newton A., et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res 2005, 65(18):8397-8405.
49. Tolmachev V., Wållberg H., Andersson K., Lundqvist H., Orlova A. The influence of Bz-DOTA and CHX-A-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114 mIn-mediated targeting therapy. Eur J Nucl Med Mol Imaging 2009, 36(9):1460-1468.
50. Tolmachev V., Mume E., Sjöberg S., Frejd F.Y., Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding. Eur J Nucl Med Mol Imaging 2009, 36(4):692-701.
51. Persson M., Tolmachev V., Andersson K., Gedda L., Sandström M., Carlsson J. [177Lu]pertuzumab. Experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005, 32(12):1457-1462.